HOT NEWS
Boehringer Ingelheim launches 'Lean-to-Clinic' program for fast drug product sup... » Boehringer Ingelheim has expanded its biopharmaceutical cell line development services and provides ...
43 research talents awarded scholarships to help secure Denmark's future » 43 of Denmark's most talented students in the biotechnological and pharmaceutical sciences will toda...
Novartis drug Signifor® recommended by CHMP for EU approval » The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) ado...
Genzyme Announces European Approval of Framingham Manufacturing Plant » Sanofi (EURONEXT: SAN and NYSE: SNY) and its subsidiary Genzyme announced today that the European Me...
AstraZeneca and IMS Health announce real-world evidence collaboration in Europe » AstraZeneca has entered into a three-year collaboration agreement with IMS Health, the leading provi...
MyAsthma App - a New Dimension in Asthma Control » GlaxoSmithKline (GSK) has announced the launch of MyAsthma, the UK's first, free personalised health...
Shire's Venvanse® (lisdexamfetamine dimesylate) Marketing Application accepted ... » Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced...
Bayer's Xarelto® (Rivaroxaban) Submitted for EU Marketing Authorisation for Sec... » Bayer HealthCare has submitted an application for marketing authorization to the European Medicines ...
Avastin receives EU approval for the treatment of women with newly diagnosed, ad... » Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the European Commission has approved Avastin (beva...
First-of-its-Kind Endovascular Trial of the Investigational Esprit(TM) Therapy » Abbott (NYSE: ABT) today announced the initiation of ESPRIT I, a first-of-its-kind clinical trial in...
AstraZeneca
AstraZenecaAstraZeneca is a major international healthcare business engaged in research, development, manufacturing and marketing of prescription pharmaceuticals and supplier for healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies with healthcare sales of US $29.55 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infection product sales. AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4Good Index. For more information visit www.astrazeneca.com.

AstraZeneca RSS Channel
Title Filter     Display # 
# Article Title Hits
1 AstraZeneca and IMS Health announce real-world evidence collaboration in Europe 1447
2 Groundbreaking scientific collaboration gives UK academia access to compounds to advance medical research 2406
3 KOMBOGLYZE™ receives marketing authorisation in the European Union 2386
4 CAPRELSA™ (vandetanib) receives positive CHMP opinion 2338
5 AstraZeneca to present new healthcare economics data demonstrating cost-effectiveness of BRILIQUE at ISPOR EU 3542
6 BRILIQUE receives a positive preliminary medical benefit assessment 4345
7 Additional Analyses from PLATO Presented at ESC Congress 3591
8 Positive agreement received for approval of AXANUM in Europe 4757
9 AstraZeneca extends its investment in Russia with new predictive science centre in St Petersburg 4985
10 AstraZeneca and Heptares collaborate to investigate important GPCR drug targets 5410
11 Health economics substudy of PLATO shows BRILIQUE to be a cost effective treatment 5273
12 European Commission approves nasal spray vaccine FLUENZ 6482
13 AstraZeneca and Abbott end license agreement for the development of Certriad 6219
14 European Commission Approves Brilique™ (Ticagrelor Tablets) 6586
15 Positive agreement received for approval of VIMOVO in Europe 6845
16 BRILIQUE (ticagrelor) receives positive opinion from European CHMP for the treatment of Acute Coronary Syndromes 6587
17 European Commission Issues Positive Decision for Approval of Seroquel XR 6191
18 Genetic substudy shows fewer major cardiovascular events with ticagrelor (BRILINTA) 5893
19 AstraZeneca and MRC Technology Form Strategic Alliance in Discovery Research 4478
20 AstraZeneca Submits Marketing Authorisation Application To European Union For Cardiovascular Drug Axanum 5238
 
  • «
  •  Start 
  •  Prev 
  •  1 
  •  2 
  •  Next 
  •  End 
  • »
Page 1 of 2
Bookmark and Share